Background: Hand-foot syndrome (HFS) is the most common adverse event induced by capecitabine. Some clinicians think that HFS is a type of inflammation limited to the hands and feet and can be prevented with a COX-2 inhibitor (celecoxib).
introduction
The use of 5-fluorouracil (5-FU) had been an integral part of many cytotoxic regimens for the treatment of malignant disease over the past five decades [1] . The oral pro-drug to fluorouracil (also called capecitabine; Hoffmann-La Roche Inc., Switzerland) showed effectiveness in the treatment of colorectal cancer with a disease-free survival that was at least as effective as fluorouracil-plus-leucovorin treatment [2] . Capecitabine alone or combined with oxaliplatine (Sanofi-Aventis, Belgium), were recommended by the NCCN Guideline 2010 for use as adjuvant chemotherapy for colorectal cancer patients.
Although capecitabine is generally well tolerated, hand-foot syndrome (HFS) is the most common clinical adverse event. HFS or hand-to-foot syndrome, also called palmar-plantar erythrodysesthesia, is a distinctive and relatively frequent dermatologic toxic reaction associated with certain chemotherapeutic agents [3] . HFS was first reported in 1974 by Zuehlke in a patient who developed a syndrome of 'erythematous eruption on the palms and soles' while receiving mitotane [4] . In the 1980s, HFS was referred to as chemotherapy-induced acral erythema and appeared to be associated with cutaneous exposure to a variety of chemotherapy drugs [5] . The incidence of HFS associated with capecitabine ranged from 50% to 60%, and the incidence of severe HFS ( ‡grade 3) was ranged from 10% to 17% [3, 6] . There were many methods to prevent and reverse HFS, including interruption of the therapy, dose reduction, and local application of deratolytic agent and so on, but there were still 57% and 11% of patients, respectively, who were forced to discontinue therapy in clinical trials [7] .
The mechanism of HFS is still unknown, but most clinicians consider it to be a type of inflammation [6] . Edward conducted a retrospective study comparing the incidences of HFS in 67 patients with metastatic colorectal cancer who took capecitabine with or without a COX-2 inhibitor (celecoxib; Pfizer Pharmaceuticals LLC, Puerto Rico). The group treated with capecitabine and celecoxib had a significantly reduced frequency of HFS of ‡ grade 1 (12.5% versus 34.3%, P = 0.037) and a non-statistical but marked reduction in the frequency of ‡ grade 2 HFS (3.1% versus 17.1%, P = 0.11) compared with the capecitabine group [7] . It is very hard to say whether celecoxib should be used for the treatment of HFS because the prospective clinical data is still limited. We designed this study to compare the incidence and severity of HFS and other toxicity in 139 patients with stage II or III colorectal cancer who received capecitabine with or without celecoxib at Sun Yat-Sen University Cancer Center.
materials and methods
The study was designed as a single-center, randomized prospective clinical trial ( Figure 1 ). The aim of this study was to explore the ability of celecoxib to prevent HFS induced by capecitabine. Edward Lin reported that the incidence of ‡ grade 1 HFS was 0.343 and 0.125, respectively, in the capecitabine group and the capecitabine combined with celecoxib group. We calculated that the sample size of this study should be 130 patients to detect hazard rates with 90% power (b = 0.01) and a two-sided significance level of (a = 0.05). Based on our previous experience, we assumed that the follow-up rate of the study would be 15%, requiring the randomization of 150 patients.
This study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and the laws and regulations of China. This study was approved by the appropriate ethics committee of Sun Yat-Sen University Cancer Center. Full written informed consent was obtained from all the patients before their participation in the study. Eligible patients were ‡18 years old with no cardiovascular diseases, pathologically confirmed stage II-III colorectal cancer and fully recovered after curative resection within 8 weeks. All patients were advised and willing to receive adjuvant chemotherapy. All patients then consented to a rapid and cost-effective reversed phase high-performance liquid chromatography for the quantification of dihydropyrimidine dehydrogenase (DPD) in their plasma. The patients were then randomized to receive oral celecoxib 200 mg twice daily. The dose of celecoxib was based on a limited number of case reports [7, 8] . Randomization was stratified based on two different chemotherapy regimes (capecitabine alone or capecitabine combined with oxaliplatine), which was decided by the clinicians. Randomization was conducted by an SPSS 13.0 random number table.
The Xelox regimen consisted of a 3-h i.v. infusion of oxaliplatin 130 mg/m 2 on day 1 and oral capecitabine 1000 mg/m 2 twice daily, given for 14 days of 3 weeks cycle (day 1 to day 14), for total of six to eight cycles (depending on whether the patients receive neoadjuvant chemotherapy or not). The capecitabine monotherapy regimen consisted of oral capecitabine 1250 mg/m 2 twice daily, given for 14 days of 3 weeks cycle, for total of six to eight cycles. Patient education, including how to prevent a side-effect event and how to describe the symptoms after chemotherapy, was conducted by an investigator before the first cycle of chemotherapy. Patients were monitored weekly with telephone calls from the investigator in charge and clinic visits every 3 weeks, using version 4.0 of the NCI CTCAE (HFS grading in Table 1 ). The grading of any adverse event was conducted by two experienced clinicians. Treatment modifications were based on the most severe adverse events observed during the previous treatment cycle. Chemotherapy treatment was paused if any grade 2 adverse event was observed. The dose-modification schema for capecitabine and XELOX are described as follows. The dose of oxaliplatin and capecitabine were reduced to 75% of the initial dose for any grade 3 adverse event. The chemotherapy was discontinued in the case of grade 4 adverse event.
After all the patients completed follow-up, all the data collected were analyzed by SPSS 13.0. The v 2 test, continuity correction v 2 test, and
Fisher's exact tests were used to assess the treatment effect of celecoxib on the incidence and severity of HFS and other adverse events. Inverted Kaplan-Meier curves and the log-rank test were used to determine the relationship and difference between the time of onset time of HFS in different groups. The significance of variables was tested using a multivariate Cox's regression. A P value <0.05 was considered to be statistically significant. All statistical analyses were carried out by SPSS 13.0. Figure 1 . Protocol scheme of the study design. Table 2 .
We compared all the adverse events in the study and found that the incidence of ‡ grade 1 and ‡ grade 2 HFS differed significantly between the capecitabine group and capecitabine/ celecoxib (74.6% versus 57.4%, P = 0.034, 29.6% versus 14.7% P = 0.035). The difference in the incidence of grade 3 HFS between the groups was not significant (8.5% versus 2.9% P = 0.303). The capecitabine/celecoxib group included more patients with grade 3 thrombocytopenia, but this trend was not significant (3 versus 0, P = 0.228). The incidence of other adverse events were nearly the same between the groups. More details are presented in Table 3 .
We used Kaplan-Meier log-rank to estimate the mean number of chemotherapy cycles and the time of onset time of HFS between groups. We found that the mean number of chemotherapy cycles until the development of ‡ grade 1 HFS was 4.336 in the capecitabine/celecoxib group and 5.852 in the capecitabine group (P < 0.001). The combined use of celecoxib could affect the incidence of ‡ grade 1 and 2 HFS (4.336 versus 5.852, P < 0.001 and 7.156 versus 7.640, P = 0.003; Figure 2 and Figure 3 , respectively). Other potential prognostic factors, including sex, age, body mass index (BMI), tumor location, pathology type, stage of tumor and dose-intensity of capecitabine, showed no statistic difference in any grade of HFS, except for level of DPD in ‡ grade 1and 2 HFS (P = 0.048 and P = 0.014; Table 4 ).
We used multivariate Cox proportional hazards regression analysis to detect all the clinical factors that were potential Table 5 ).
discussion
Capecitabine is used more and more frequently as a chemotherapy agent for colorectal cancer, especially in neoadjuvant and adjuvant chemotherapy. HFS is reported to be the most common adverse event in patients receiving capecitabine treatment. The incidence of HFS in clinical trials ranges from 16.2% to 68% [9, 10] . After analyzing three phase III trials including SO14796, SO14695, and NO. 16968, it was determined that USA patients experienced more HFS than non-USA patients (any grade HFS: 18% versus 12%, grade 3 HFS: 11% versus 1%) [11] . In our study, we found that the incidence of ‡ grade 1 HFS was 74.6% in the capecitabine alone group and 57.4% in the capecitabine/celecoxib group as reported previously in a Korea clinical trial (any grade HFS incidence rate: 77.8%-81.7%, at least grade 2 HFS: 30.6%-31.7%) [12] . Compared with USA patients (>grade 1 HFS incidence was 34.3% and >grade 2 HFS incidence was 17.1%), more Chinese patients experienced grade 1 and grade 2 HFS [7, 8] . USA patients experienced more grade 3 HFS than did Asian patients. Different populations may metabolize the same drug differently, leading to variability in the incidence of adverse events [13] . Possible reasons for this phenomenon include reporting bias in different clinical trials, dietary folate intake, and genetic polymorphisms [11] . The mechanism of HFS is unknown. Most of clinicians believe that HFS results from inflammation in the hands and feet [7, 8] . The inflammation reaction may be triggered directly or indirectly by capecitabine or a by-product of capecitabine. Edward hypothesized that HFS was a type of inflammation mediated by over-expression of COX-2 in the hands and feet. His retrospective study, which includes 67 patients, proved that selected COX-2 inhibitor can reduce the frequency of HFS. There is only limited evidence to support this hypothesis, so it is necessary to conduct prospective clinical trial to test its validity.
Until recently, there has been no effective way to prevent or reverse HFS. Currently, the mainstay of the management of HFS is the interruption of therapy and dose reduction [14] . Some research has shown that high-dose pyridoxine seems to be effective in the prevention of HFS [15] [16] [17] [18] [19] . Several months ago, it was reported that pyridoxine was not effective in preventing HFS induced by capecitabine (30.6% versus 31.7%, P = 0.78) [12] . Other approaches to the management of HFS, such as Chinese medicine, body lotion, topical or systemic corticosteroids, had been reported effective without enough researches supported [20] . Edward's study, which involved 
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longer follow-up showed that capecitabine plus celecoxib resulted in a 17% incidence of grade 2/3 HFS, 90% of these cases occurred after 6 months. Median HFS onset and peak occurred at 3.8 and 6 months, respectively. In contrast, patients experienced HFS onset (93%) and most severe episode (67.9%) within 6 weeks of capecitabine treatment at 1250 mg/m 2 /day; the incidence of grade 3 HFS was as high as 17% [13] . Our study showed that celecoxib combined with capecitabine can prevent HFS (74.6% versus 57.4%, P = 0.034 for ‡ grade 1 HFS and 29.6% versus 14.7% for ‡ grade 2HFS). However, there was no statistic difference between groups in the incidence of grade 3 HFS. A limited number of grade 3 patients and different mechanisms underlying grade 3 HFS may be the reason for this phenomenon. We also found that selected COX-2 inhibitor caused no serious side-effect in any of the patients receiving celecoxib. Based on the hypothesis and the result of our study, celecoxib can be used usefully and safely in capecitabine-based chemotherapy.
The risk factors of HFS induced by 5-FU have been reported to be older age, female sex, improved performance, continuous infusion of chemotherapy agents, and the inclusion of docetaxel in the chemotherapy regimen [6, 21] . We use Kaplan-Meier log-rank to detect all potential risk factors. The related literature provided sex, age, BMI, tumor location, pathology type, tumor stage, DPD enzyme level, and combined use of celecoxib as potential risk factors [6] . We found that the combined use of celecoxib was the independent risk factor for the development of ‡ grade 1 HFS and grade 2 HFS (4.336 versus 5.852, P < 0.001, 7.156 versus 7.640, P = 0.003). The level of DPD enzyme in patients' blood serum also differed significantly in ‡ grade 1 and 2 HFS (P = 0.048, P = 0.014). Cox multiple analysis showed that combination with celecoxib was the only factor that affected the incidence of ‡ grade 1 HFS (HR: 0.483, 95% CI 0.338-0.692, P < 0.001) and ‡ grade 2 HFS (HR: 0.29, 95% CI 0.141-0.598, P = 0.001). The result showed that female sex and older age may be the predictors for 5-FUinduced HFS but not for capecitabine-induced HFS. Remarkably, dose-intensity of capecitabine had no relationship to HFS. This may be because of the limited number of the patients that were taking 2500 mg/m 2 . In our study, all patients received celecoxib 200 mg twice a day for 14 days per cycle. No patients experienced any grade of cardiovascular side-effects. The safety of celecoxib has been proven by many multicentre clinical trials [22] , but we still recommend that celecoxib should be used on patients with no history of cardiovascular disease.
In summary, local inflammation which is limited to hands and feet may cause HFS. Based on the results of our study, we recommend that a selected COX-2 inhibitor (e.g. celecoxib) can be used effectively and safely.
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